First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imag...( Excellent results obtained with a ...),Health

Excellent results obtained with a newly cleared device to identify the lipid core (fatty) coronary plaques of interest that are associated with

complications of coronary stenting

BURLINGTON, Mass., May 15 /PRNewswire/ -- InfraReDx, Inc. today announced that physicians at Beaumont Hospital in Royal Oak, Mich., have successfully used its LipiScan(TM) Coronary Imaging System in a patient undergoing a cardiac catheterization. This is the first patient in the world in whom it has been possible to assess the chemical composition of coronary artery plaques and utilize such information to assist in the management of coronary artery disease.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080515/NETH104 )

Dr. Daniel Schultz, Director of the FDA Center for Devices and Radiological Health, has stated, "This is the first device that can help assess the chemical make-up of coronary artery plaques and help physicians identify those plaques with lipid cores, which may be of particular concern."

Physicians at Beaumont Hospital performed the procedure on May 8, 2008 in a 70-year old male patient. The LipiScan System revealed the presence of a lipid core containing plaque not detectable by conventional diagnostic measures. This fatty plaque was located near a narrowing that required a coronary stent for the usual reasons. Because of the presence of this plaque, the physicians selected a stent that was 50 percent longer than the one that would have been used to cover the narrowing only. This longer stent covered the lipid core containing plaque and avoided placing the end of a shorter stent in the fatty plaque. Termination of a stent in a fatty plaque has been associated with clotting of the stent years after placement.

"If doctors can identify these fatty plaques, we can recommend better treatment options to patients," says Simon Dixon, M.D.
'/>"/>